Mizuho Securities analyst Salim Syed maintains $Wave Life Sciences (WVE.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 41.4% and a total average return of -2.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Wave Life Sciences (WVE.US)$'s main analysts recently are as follows:
Recent updates to the financial model for Wave Life Sciences were made following the RestorAATion-2 AATD data release and Takeda's decision not to proceed. Significant alterations include an increased likelihood of success in alpha-1 antitrypsin deficiency and the adjustment of the Huntington's disease program's ownership status, as conveyed to investors.
The firm's increased optimism on Wave Life Sciences is due to the de-risking of key programs and a higher valuation of the pipeline and technology, following encouraging updates across various therapeutic modalities.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
